Table 1.
Baseline and demographic characteristics | Semaglutide (N = 83) | Placebo (N = 83) | Total (N = 166) |
---|---|---|---|
Age (years) | 37.7 (19–55) | 38.6 (21–55) | 38.2 (19–55) |
Body weight (kg) | 77.9 (58.9–107.2) | 76.6 (59.5–99.0) | 77.3 (58.9–107.2) |
BMI (kg/m2) | 24.9 (20.5–30.0) | 25.2 (20.1–29.9) | 25.1 (20.1–30.0) |
Females, N (%) | 30 (36.1) | 37 (44.6) | 67 (40.4) |
Males, N (%) | 53 (63.9) | 46 (55.4) | 99 (59.6) |
Race, N (%) | |||
White | 78 (94.0) | 82 (98.8) | 160 (96.4) |
Othera | 5 (6.0) | 1 (1.2) | 6 (3.6) |
Data are presented as the mean with the range in parenthesis unless otherwise stated
BMI body mass index, N number of subjects
aOther includes both ‘other’ and ‘American Indian or Alaska Native’ racial groups